Replies to post #141378 on Biotech Values

[mcbio]

Anyone know of any company that had less than 12 months of cash on hand that got a good deal for a ph ii compound - (e.g. >15% royalties plus partner covers all trial costs)?

I'll submit ARRY on two occasions, once for the deal with NVS on MEK162 (http://investor.arraybiopharma.com/phoenix.zhtml?c=123810&p=irol-newsArticle&ID=1414590&highlight= ) and also with AMGN on ARRY-403 (http://investor.arraybiopharma.com/phoenix.zhtml?c=123810&p=irol-newsArticle&ID=1365735&highlight= ). And actually, both of those drugs were in Phase 1 at the time of those deals. I don't think ARRY had more than 12 months of cash at the time of those deals and, if they did, it wasn't much more.

[genisi]

Suggest the late CYPB/BLRX deal on BL-1020 qualifies if you accept the royalties of 12 to 18 percent based on sales part.

http://www.biolinerx.com/default.asp?pageid=16&itemid=47

[DewDiligence]

Anyone know of any company that had less than 12 months of cash on hand that got a good deal for a ph ii compound…?

Reata’s $450M deal with ABT for Bardoxolone (#msg-54747777) may qualify, although Reata’s pre-deal financial status isn’t precisely known because the company is private.